The contrasting effects of two antimalarial drugs on insulin secretion
Cellular and Molecular Life Sciences · 2025
DOI: 10.1007/s00018-025-05933-0 ↗At a glance
Journal article in Cellular and Molecular Life Sciences, 2025. Written by Jing Lu and 6 co-authors. Institution: Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medi…. Major MEDLINE topics: Antimalarials, Insulin Secretion, Insulin, Quinine. Cited 1 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Beijing Municipality, Cultivation Fund of Capital Medical University, Beijing Tongren Hospital Seed Funds.
Abstract (original language)
Quinolines and artemisinins are the two most important antimalarial drugs worldwide. In addition to antimalarial effects, quinine has been extensively documented to directly stimulate insulin secretion, potentially causing hypoglycemia in malaria patients undergoing treatment through the inhibition of KATP channels, and artemisinins have been recently identified as small molecules that increase insulin secretion by functionally promoting the conversion of pancreatic α cells into β cells, which is promising for the therapy of diabetes. Here, to detect the precise function of these drugs in insulin secretion, glucose-stimulated insulin secretion (GSIS) test with isolated mouse islets and insulin secretion experiment in mice were performed. Quinine was the most potent insulin secretagogue of all three quinoline drugs tested in this study. Low-dose quinine potentiated insulin secretion in a high glucose-dependent manner through KCNH6 current inhibition rather than through classical KATP inhibition. However, artemisinins did not promote insulin secretion in vitro or in vivo. In particular, artemether significantly suppressed insulin secretion, decreased Ca2+ influx and the expression levels of β-cell marker genes, contradicting the findings of previous studies suggesting that artemisinins promote the transformation of pancreatic α cells into β cells. Overall, our observations revealed the differential effects of two widely used antimalarial drugs, quinolines and artemisinins, on insulin secretion. Ascertaining the targets by which drugs affect insulin secretion may advance diabetes treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing, China. jinglu_tr@ccmu.edu.cn.
- Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing, China. jkyang@ccmu.edu.cn.
Funding
- Natural Science Foundation of Beijing Municipality
- Cultivation Fund of Capital Medical University
- Beijing Tongren Hospital Seed Funds
- National Natural Science Foundation of China
Cite
APA
Lu, J., Xiong, F., Zhang, Q., Zhao, R., Zhang, C., Wei, G., & Yang, J. (2025). The contrasting effects of two antimalarial drugs on insulin secretion. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-025-05933-0
Vancouver
Lu J, Xiong F, Zhang Q, Zhao R, Zhang C, Wei G, et al. The contrasting effects of two antimalarial drugs on insulin secretion. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-025-05933-0
BibTeX
@article{Lu2025,
author = {Lu, Jing and Xiong, Fengran and Zhang, Qianrui and Zhao, Ruxuan and Zhang, Chenyang and Wei, Gang and Yang, Jinkui},
title = {The contrasting effects of two antimalarial drugs on insulin secretion},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
doi = {10.1007/s00018-025-05933-0}
}
EUVIMED